Patent ID: 9598492
Date: 2017-03-21
CPC Classifications: A61K,A61P,C07K,C12Y,G01N

Claim:
1. A method of treating a CD22-expressing B-cell malignancy in a subject, comprising administering to the subject a therapeutically effective amount of a monoclonal antibody that specifically binds human CD22 and is conjugated to an agent that inhibits growth of malignant B cells or kills malignant B cells in the subject, the antibody comprising a heavy chain or portion thereof, which comprises an amino acid sequence comprising residues 26-35 of SEQ ID NO: 3, residues 53-61 of SEQ ID NO: 3 and residues 100-113 of SEQ ID NO: 3, and a light chain or portion thereof, which comprises an amino acid sequence comprising residues 27-32 of SEQ ID NO: 4, residues 50-52 of SEQ ID NO: 4 and residues 89-97 of SEQ ID NO: 4, wherein the therapeutically effective amount of the monoclonal antibody conjugated to the agent is an amount that inhibits growth of malignant B cells or kills malignant B cells in the subject, thereby treating the subject.